A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patients

NCT00655538 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

476

Enrollment

INDUSTRY

Sponsor class

Conditions

Coronary Heart Disease

Interventions

DRUG: Placebo
DRUG: dalcetrapib

Sponsor

Hoffmann-La Roche